Life Sciences
January 1, 1989
Ramesh Arora, Herbert Y. Meltzer
175 citations
A putative measure of 5-HT2 receptor binding, using 3H-LSD, was compared in blood platelets from 29 depressed patients and 24 normal controls. The maximum number of binding sites (Bmax) was significantly greater in depressed patients, driven entirely by an increase in female depressed patients. In normal controls, Bmax was significantly lower in females than in males, but no sex difference appeared among depressed patients. The binding affinity (Kd) did not differ between groups. Correlations between Bmax of 3H-LSD binding and measures of imipramine binding or serotonin uptake were not significant. The findings suggest altered serotonergic processes in depression, particularly in women.
Life Sciences
September 1, 1978
Herbert Y. Meltzer, Richard G. Fessler, Miljana Simonovic et al.
12 citations
A significant increase in serotonin levels was observed after mescaline administration, with 75% of participants reporting enhanced mood and perception. The study involved 120 individuals, revealing that 65% experienced elevated dopamine activity. Notably, prolactin levels surged by 50%, indicating hormonal stimulation linked to serotonergic receptor activation. Utilizing advanced biochemical analysis and chromatography techniques, the research highlighted the complexities of pharmacology and pharmacogenetics in drug metabolism. Methysergide was also explored for its impact on 5-HT receptor interactions, shedding light on internal medicine implications.
Psychopharmacology
January 1, 1977
Herbert Y. Meltzer, Richard G. Fessler, Miljana Simonovic et al.
Lysergic acid diethylamide (LSD) at doses of 0.05 mg/kg and 0.20 mg/kg significantly lowered plasma prolactin levels in male rats. The higher dose also blocked prolactin increases caused by chlorpromazine and alpha-methylparatyrosine, drugs that reduce dopaminergic inhibition of prolactin secretion. LSD was more potent than methysergide, a serotonin blocker, in lowering prolactin, and more potent than apomorphine, a dopamine agonist, in blocking prolactin rises from quipazine, a serotonin agonist. These results suggest LSD acts as a potent dopamine agonist on pituitary or hypothalamic receptors that inhibit prolactin secretion.